Developability of Biotherapeutics Computational Approaches 1st Edition by Sandeep Kumar ,Satish Kumar Singh ISBN 9781482246131 978-1482246131

Developability of Biotherapeutics Computational Approaches 1st Edition by Sandeep Kumar ,Satish Kumar Singh – Ebook PDF Instant Download/Delivery:9781482246131 ,978-1482246131
Full download Developability of Biotherapeutics Computational Approaches 1st Edition after payment

Product details: 

ISBN 10:9781482246131

ISBN 13:978-1482246131

Author:Sandeep Kumar ,Satish Kumar Singh

Biopharmaceuticals are emerging as frontline medicines to combat several life-threatening and chronic diseases. However, such medicines are expensive to develop and produce on a commercial scale, contributing to rising healthcare costs. Developability of Biotherapeutics: Computational Approaches describes applications of computational and molecular modeling techniques that improve the overall process of discovery and development by removing empiricism.

The concept of developability involves making rational choices at the pre-clinical stages of biopharmaceutical drug development that could positively impact clinical outcomes. The book also addresses a general lack of awareness of the many different contributions that computation can make to biopharmaceutical drug development.

This informative and practical reference is a valuable resource for professionals engaged in industrial research and development, scientists working with regulatory agencies, and pharmacy, medicine, and life science students and educators. It focuses primarily on the developability of monoclonal antibody candidates, but the principles described can also be extended to other modalities such as recombinant proteins, fusion proteins, antibody drug conjugates and vaccines.

The book is organized into two sections. The first discusses principles and applications of computational approaches toward discovering and developing biopharmaceutical drugs. The second presents best practices in developability assessments of early-stage biopharmaceutical drug candidates.

In addition to raising awareness of the promise of computational research, this book also discusses solutions required to improve the success rate of translating biologic drug candidates into products available in the clinic. As such, it is a rich source of information on current principles and practices as well as a starting point for finding innovative applications of computation towards biopharmaceutical drug development.

Table of contents: 

PRINCIPLES OF BIOPHARMACEUTICAL INFORMATICS

Biopharmaceutical Informatics: Applications of Computation in Biologic Drug Development
Sandeep Kumar, Russell H. Robins, Patrick M. Buck, Timothy P. Hickling, A. Mary Thangakani, Li Li, Satish K. Singh, and M. Michael Gromiha

Computational Methods in the Optimization of Biologic Modalities
Surjit B. Dixit

Understanding, Predicting, and Mitigating the Impact of Posttranslational Physiochemical Modifications, Including Aggregation, on the Stability of Biopharmaceutical Drug Products
Neeraj J. Agrawal and Naresh Chennamsetty

Preclinical Immunogenicity Risk Assessment of Biotherapeutics
Tim D. Jones, Anette C. Karle, and Matthew P. Baker

Application of Mechanistic Pharmacokinetic–Pharmacodynamic Modeling toward the Development of Biologics
Pratap Singh, Abhinav Tiwari, Anson K. Abraham, and Anup Zutshi

Challenges in High-Concentration Biopharmaceutical Drug Delivery: A Modeling Perspective
Anuj Chaudhri

DEVELOPABILITY PRACTICES IN THE BIOPHARMACEUTICAL INDUSTRY

Best Practices in Assessment of Developability in Biopharmaceutical Candidates
Steffen Hartmann and Hans P. Kocher

Best Practices in Developability Assessments of Therapeutic Protein Candidates in the Biopharmaceutical Industry
Nicolas Angell, Randal R. Ketchem, Kristine Daris, Jason W. O’Neill, and Kannan Gunasekaran

Best Practices in Assessing the Developability of Biopharmaceutical Candidates
Juan C. Almagro and Alessandro Mascioni

Developability Assessment Workflows to De-Risk Biopharmaceutical Development
Jesús Zurdo, Andreas Arnell, Olga Obrezanova, Noel Smith, Thomas R. A. Gallagher, Ramón Gómez de la Cuesta, and Ben Locwin

People also search for:

developability assessment of therapeutic antibodies

30 years of biotherapeutics development-what have we learned

development of biopharmaceutical drug-device products

developability of biopharmaceuticals

future of biotherapeutics

Tags: Sandeep Kumar , Satish Kumar Singh, Developability, Biotherapeutics